Tenapanor hydrochloride is a Small Molecule owned by Ardelyx, and is involved in 33 clinical trials, of which 29 were completed, 3 are ongoing, and 1 is planned.
Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium
Tenapanor acts as a NHE3 inhibitor. NHE3 is localized to the apical membrane and play important roles in intestinal Na+ absorption with varying activities in different segments of the gastrointestinal tract. The Na+/H+ exchanger 3 mediates the majority of the NaCl and NaHCO3 absorption in the mammalian ileum. In normal digestive physiology, Inhibition of NHE3 regulation leads to inhibition of Na+ absorption, resulting in decreased water absorption and diarrhea.
The revenue for Tenapanor hydrochloride is expected to reach a total of $5.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tenapanor hydrochloride NPV Report.
Tenapanor hydrochloride is originated and owned by Ardelyx. Kyowa Kirin is the other company associated in development or marketing of Tenapanor hydrochloride.
Tenapanor hydrochloride Overview
Tenapanor hydrochloride (Ibsrela) belongs to 4-phenyltetrahydroisoquinolines. It is formulated as tablets for oral route of administration. Ibsrela is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Tenapanor is under development for the treatment of hyperphosphatemia in hemodialysis patients, irritable bowel syndrome and hyperphosphatemia in patients with end-stage renal disease. The drug candidate was also under development for the treatment of chronic kidney disease patients with type 2 diabetes mellitus and albuminuria.
Ardelyx Overview
Ardelyx, is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US. Ardelyx, is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.
Quick View – Tenapanor hydrochloride
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies | |
Highest Development Stage |
|